 Patients will have peripheral blood PB chimerism tested upon engraftment. A confirmatory test from PB and bone marrow BM will be done on day 457. Minimal residual disease MRD will be examined by immunoflow, FISH, cytogenetics or PCR. Patients with positive MRD will be on a faster schedule of immune intervention than patients with negative MRD. Interventions will be carried on until 1 year post transplant. If confirmatory testing shows no evidence of MRD and full donor chimerism is present in all subsets, the patient will be part of the observation group and be observed until 2 years post transplant. Chimerism will be repeated at 12 and 24 months post transplant. If the patient has mixed chimerism on both confirmatory tests PB and BM, the patient will be part of the intervention group and fast withdrawal of immunosuppression will be initiated. If the patient has mixed chimerism on one of the confirmatory tests PB or BM, the test will be repeated in 2 weeks and the patient will proceed with either observation or intervention, based on the result of the repeated test. Patients will be followed for the incidence of acute and chronic Graft Versus Host Disease GVHD and relapse until 2 years post transplant. The study will be considered successful if the relapse rate at 2 years post transplant is 20 for the entire study or 40 for the intervention group. 